LT4048278T - Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną - Google Patents

Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną

Info

Publication number
LT4048278T
LT4048278T LTEPPCT/US2020/056408T LTUS2020056408T LT4048278T LT 4048278 T LT4048278 T LT 4048278T LT US2020056408 T LTUS2020056408 T LT US2020056408T LT 4048278 T LT4048278 T LT 4048278T
Authority
LT
Lithuania
Prior art keywords
morpholinoazetidin
dioxopiperidin
isoindoline
benz
dione
Prior art date
Application number
LTEPPCT/US2020/056408T
Other languages
English (en)
Inventor
Maria Soraya ANTON
Tonia J. Buchholz
Shailaja Kasibhatla
Antonia Lopez-Girona
Rama Narla
Michael POURDEHNAD
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of LT4048278T publication Critical patent/LT4048278T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2020/056408T 2019-10-21 2020-10-20 Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną LT4048278T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924028P 2019-10-21 2019-10-21
PCT/US2020/056408 WO2021080935A1 (en) 2019-10-21 2020-10-20 Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
LT4048278T true LT4048278T (lt) 2023-12-11

Family

ID=73449175

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2020/056408T LT4048278T (lt) 2019-10-21 2020-10-20 Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną

Country Status (21)

Country Link
US (2) US11666579B2 (lt)
EP (1) EP4048278B1 (lt)
JP (1) JP7581346B2 (lt)
KR (1) KR20220103722A (lt)
CN (2) CN115919871A (lt)
BR (1) BR112022007417A2 (lt)
CA (1) CA3154504A1 (lt)
DK (1) DK4048278T3 (lt)
ES (1) ES2967929T3 (lt)
FI (1) FI4048278T3 (lt)
HR (1) HRP20231487T1 (lt)
HU (1) HUE064768T2 (lt)
IL (1) IL292266A (lt)
LT (1) LT4048278T (lt)
MX (1) MX2022004683A (lt)
PL (1) PL4048278T3 (lt)
PT (1) PT4048278T (lt)
RS (1) RS64936B1 (lt)
SI (1) SI4048278T1 (lt)
SM (1) SMT202300428T1 (lt)
WO (1) WO2021080935A1 (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919870B (zh) * 2019-10-21 2024-07-02 新基公司 化合物在制备用于治疗慢性淋巴细胞白血病的药物中的用途
PL4048278T3 (pl) * 2019-10-21 2024-03-18 Celgene Corporation Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu
WO2021080931A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneand salts thereof, and compositions comprising the same and their use
AU2020370039B2 (en) * 2019-10-21 2026-02-19 Celgene Corporation Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752124A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
KR20160090903A (ko) * 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
WO2015085172A2 (en) * 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
EP4467143B1 (en) 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
RU2017135686A (ru) * 2017-10-06 2019-04-08 Закрытое Акционерное Общество "Биокад" Ингибиторы рецептора эпидермального фактора роста
FI3784663T3 (fi) * 2018-04-23 2023-10-06 Celgene Corp Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CN115919870B (zh) 2019-10-21 2024-07-02 新基公司 化合物在制备用于治疗慢性淋巴细胞白血病的药物中的用途
PL4048278T3 (pl) * 2019-10-21 2024-03-18 Celgene Corporation Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu
AU2020370039B2 (en) 2019-10-21 2026-02-19 Celgene Corporation Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

Also Published As

Publication number Publication date
DK4048278T3 (da) 2024-01-08
FI4048278T3 (fi) 2023-12-19
JP7581346B2 (ja) 2024-11-12
PT4048278T (pt) 2024-01-12
WO2021080935A1 (en) 2021-04-29
AU2020372330B2 (en) 2026-02-05
IL292266A (en) 2022-06-01
CA3154504A1 (en) 2021-04-29
EP4048278A1 (en) 2022-08-31
AU2020372330A1 (en) 2022-05-19
CN115919871A (zh) 2023-04-07
ES2967929T3 (es) 2024-05-06
SI4048278T1 (sl) 2024-01-31
RS64936B1 (sr) 2024-01-31
BR112022007417A2 (pt) 2022-07-12
US20230277548A1 (en) 2023-09-07
CN115087448A (zh) 2022-09-20
SMT202300428T1 (it) 2024-01-10
HRP20231487T1 (hr) 2024-03-01
JP2022552882A (ja) 2022-12-20
HUE064768T2 (hu) 2024-04-28
EP4048278B1 (en) 2023-11-01
US12178822B2 (en) 2024-12-31
US11666579B2 (en) 2023-06-06
KR20220103722A (ko) 2022-07-22
PL4048278T3 (pl) 2024-03-18
US20210113577A1 (en) 2021-04-22
MX2022004683A (es) 2022-05-10

Similar Documents

Publication Publication Date Title
IL287145A (en) Methods for treating non-Hondkin's lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 , 3-dione
PT4048278T (pt) Métodos de tratamento de doenças malignas hematológicas utilizando 2 --(2,6 dioxopiperidin 3 il) 4 --((2 fluoro 4 --((3 morfolinoazetidin 1 il)metil)be nzil)amino)isoindolina 1,3 diona¿
IL269586A (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
IL278854A (en) Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile
IL292265A (en) Methods for treating chronic lymphocytic leukemia using 2-(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3- discussion
HUE046008T2 (hu) I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
CY1120454T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
MX2017007065A (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.
SI3580208T1 (sl) Derivati 2-(3-(1H-benzo(d)imidazol-1-il)propil)piperidin-3-ol in sorodne spojine kot zaviralci PRS za zdravljenje na primer raka
IL292258A (en) Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them
PH12020500211A1 (en) Methods of treating behavior alterations
IL284680A (en) Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same
IL284509A (en) Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide
SG11202107438WA (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
HK40066611A (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
HK40077318A (en) Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
IL307942A (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline -1, 3-dione
HK40077317A (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
HK40108967A (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
HK40079627A (en) Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
HK40060641A (en) Methods and compositions for treating hepatocellular carcinoma using antisense